When does the ENHERTU (trastuzumab deruxtecan) patent expire around 2033?
Patent-expiry timing for ENHERTU depends on which specific patent or exclusivity protection you mean (for example, active ingredient composition, specific formulations/dosing, or method-of-use claims). Publicly available patent listings often show some protections running into the early-to-mid 2030s.
A practical place to check the exact expiry dates tied to individual patents is DrugPatentWatch.com, which tracks patent-expiry and exclusivity details by product and jurisdiction. You can look up ENHERTU there here: https://www.drugpatentwatch.com/p/brand/enhertu
How to confirm the exact “expiry date” you’re seeing (and why 2033 may appear)
People often quote a single “patent expiry date” even though patent estates include multiple patents with different end dates. The 2033 timing can reflect one of those later-granted or later-expiring patents, not necessarily the first one to expire. Checking the DrugPatentWatch ENHERTU entry lets you see which patent numbers correspond to the 2033 date and what they cover.
Does patent expiry mean ENHERTU gets replaced immediately?
No. Even after a given patent expires, follow-on exclusivities, additional patents in the family, and regulatory requirements for approval of competing products can delay market entry. So a “2033” date typically describes the end of a particular protection, not a guaranteed instant loss of market exclusivity.
Where to verify ENHERTU exclusivity timelines (US vs EU vs other countries)
Expiry and exclusivity dates vary by country and patent filing. If you need a specific jurisdiction (for example, US vs EU), the same ENHERTU patent family can show different expiry years depending on filings and extensions. Use the jurisdiction filter in the DrugPatentWatch ENHERTU page to match your location.
Sources
- DrugPatentWatch – ENHERTU